The U.S. Food and Drug Administration has approved high-dose glatiramer acetate (40 mg/day) with a new three times per weekly dose schedule. Read More
Latest News
Deep-brain stimulation in PD: meta-analysis
July 23, 2014A new meta-analysis has concluded that deep-brain stimulation (DBS) is effective in the control of motor signs and for improving functionality and quality of life in patients with Parkinson’s disease (Perestelo-Perez et al. J Neurol 2014; epublished February 2, 2014). Data were analysed from six randomized controlled trials comparing DBS with medication versus medications alone (n=1184).
The outcome measures included motor function, time without dyskinesias, reduction in levodopa-equivalent dosing, neurocognitive and psychiatric effects, and effect on quality of life. Read More
Managing epilepsy: are patients satisfied?
July 23, 2014Few studies have examined whether patients with epilepsy are satisfied with how they are managed. A University of Calgary study has investigated this issue in a systematic review of the literature (Wiebe et al. Epilepsia 2014; epublished February 6, 2014). Read More
APA 2014: New Research – Part 2
July 9, 2014Highlights of the American Psychiatric Association (APA) 167th annual meeting, New York NY, May 3-7, 2014 – The following is a summary of some noteworthy studies presented at this year’s APA annual meeting. Please go to Part 1 to read our coverage of antidepressant treatment trials.
Bipolar disorder
Schizophrenia
Miscellany and curiosities
Read More